Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer.
Henshall SM, Afar DE, Rasiah KK, Horvath LG, Gish K, Caras I, Ramakrishnan V, Wong M, Jeffry U, Kench JG, Quinn DI, Turner JJ, Delprado W, Lee CS, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Mack DH, Sutherland RL. Henshall SM, et al. Among authors: afar de. Oncogene. 2003 Sep 4;22(38):6005-12. doi: 10.1038/sj.onc.1206797. Oncogene. 2003. PMID: 12955079
Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer.
Afar DE, Bhaskar V, Ibsen E, Breinberg D, Henshall SM, Kench JG, Drobnjak M, Powers R, Wong M, Evangelista F, O'Hara C, Powers D, DuBridge RB, Caras I, Winter R, Anderson T, Solvason N, Stricker PD, Cordon-Cardo C, Scher HI, Grygiel JJ, Sutherland RL, Murray R, Ramakrishnan V, Law DA. Afar DE, et al. Mol Cancer Ther. 2004 Aug;3(8):921-32. Mol Cancer Ther. 2004. PMID: 15299075
E-selectin up-regulation allows for targeted drug delivery in prostate cancer.
Bhaskar V, Law DA, Ibsen E, Breinberg D, Cass KM, DuBridge RB, Evangelista F, Henshall SM, Hevezi P, Miller JC, Pong M, Powers R, Senter P, Stockett D, Sutherland RL, von Freeden-Jeffry U, Willhite D, Murray R, Afar DE, Ramakrishnan V. Bhaskar V, et al. Among authors: afar de. Cancer Res. 2003 Oct 1;63(19):6387-94. Cancer Res. 2003. PMID: 14559828
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, van Abbema A, Jesaitis L, Caras I, Law D, Weller E, Xie W, Richardson P, Munshi NC, Mathiot C, Avet-Loiseau H, Afar DE, Anderson KC. Tai YT, et al. Among authors: afar de. Blood. 2008 Aug 15;112(4):1329-37. doi: 10.1182/blood-2007-08-107292. Epub 2007 Sep 28. Blood. 2008. PMID: 17906076 Free PMC article.
Epithelial membrane protein-1 is a biomarker of gefitinib resistance.
Jain A, Tindell CA, Laux I, Hunter JB, Curran J, Galkin A, Afar DE, Aronson N, Shak S, Natale RB, Agus DB. Jain A, et al. Among authors: afar de. Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11858-63. doi: 10.1073/pnas.0502113102. Epub 2005 Aug 8. Proc Natl Acad Sci U S A. 2005. PMID: 16087880 Free PMC article.
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy JD Jr, Barlogie B, Yaccoby S, Afar DE. van Rhee F, et al. Among authors: afar de. Mol Cancer Ther. 2009 Sep;8(9):2616-24. doi: 10.1158/1535-7163.MCT-09-0483. Epub 2009 Sep 1. Mol Cancer Ther. 2009. PMID: 19723891 Free PMC article. Clinical Trial.
51 results